News By Tag Industry News News By Location Country(s) Industry News
|  Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030The success of CTLA4, PD-1, and PD-L1 inhibitors paved the way for researchers to explore the vast therapeutic potential of immune checkpoint modulation, enabling the discovery of product candidates against clinical conditions beyond oncology
By: Roots Analysis Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well. Key Market Insights More than 300 immune checkpoint inhibitors and stimulators are currently under development Nearly 50% of pipeline drugs are being evaluated in the clinical phase and 40% are in preclinical / discovery stage. It is worth mentioning that most of the product candidates are being developed against CD47 immune checkpoint. Further, majority of these therapies (60%) are designed for intravenous administration. Several big pharma players have next generation immune checkpoint therapy-based initiatives Over 30 companies engaged in this domain represent large / very large businesses. These companies are developing drugs, either in-house or in partnership with other players, across 25+ immune checkpoint targets for 30+ disease indications. Maximum number of partnerships were observed in 2019 indicating an increase in the activity in this domain. Majority of these agreements were reported to be research and licensing, representing over 22% of the total number of instances. More than 40% of the total amount was awarded under the R01 mechanism (which supports research projects). The NCI, NHLBI, NIAID, and NINDS emerged as key organizations that have offered financial support for time periods exceeding 20 years as well. In the last 9 years, over 550 clinical trials evaluating next generation immune checkpoint modulators have been registered The report features inputs from eminent industry stakeholders, according to whom there is a growing need to evaluate the potency and therapeutic benefits of candidate therapies targeting immune checkpoints beyond PD-1 and PD-L1. The report includes detailed transcripts of the discussions held with industry experts. For additional details, please visit https://www.rootsanalysis.com/ Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@ End
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number